Merck KGaA (MKGAF)
(Delayed Data from OTC)
$165.33 USD
+6.97 (4.40%)
Updated Apr 25, 2024 02:53 PM ET
4-Sell of 5 4
A Value F Growth D Momentum C VGM
Income Statements
Fiscal Year end for Merck KGaA falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 22,721 | 23,424 | 23,292 | 20,029 | 18,090 |
Cost Of Goods | 9,308 | 8,984 | 8,697 | 7,808 | 6,727 |
Gross Profit | 13,413 | 14,440 | 14,595 | 12,221 | 11,364 |
Selling & Adminstrative & Depr. & Amort Expenses | 9,506 | 9,726 | 9,652 | 8,812 | 8,989 |
Income After Depreciation & Amortization | 3,907 | 4,714 | 4,943 | 3,410 | 2,374 |
Non-Operating Income | 213 | 95 | 73 | 50 | 109 |
Interest Expense | 349 | 292 | 375 | 455 | 539 |
Pretax Income | 3,771 | 4,517 | 4,642 | 3,004 | 1,943 |
Income Taxes | 704 | 999 | 1,016 | 728 | 493 |
Minority Interest | 11 | 15 | 12 | 8 | 3 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 3,067 | 3,518 | 3,626 | 2,278 | 1,452 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 31 |
Net Income (GAAP) | 3,056 | 3,503 | 3,614 | 2,270 | 1,480 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 5,942 | 6,853 | 7,028 | 5,624 | 4,552 |
Depreciation & Amortization (Cash Flow) | 2,035 | 2,139 | 2,085 | 2,214 | 2,177 |
Income After Depreciation & Amortization | 3,907 | 4,714 | 4,943 | 3,410 | 2,374 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 434.80 | 434.77 | 434.57 | 434.80 | 434.21 |
Diluted EPS Before Non-Recurring Items | 9.19 | 10.59 | 10.32 | 7.65 | 6.23 |
Diluted Net EPS (GAAP) | 7.02 | 8.06 | 8.32 | 5.22 | 3.40 |
Fiscal Year end for Merck KGaA falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 5,627.63 | 5,630.29 | 5,781.30 | 5,681.51 |
Cost Of Goods | NA | 2,504.48 | 2,353.12 | 2,332.37 | 2,117.82 |
Gross Profit | NA | 3,123.15 | 3,277.17 | 3,448.94 | 3,563.69 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2,455.68 | 2,206.19 | 2,391.25 | 2,452.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 667.47 | 1,070.98 | 1,057.69 | 1,110.97 |
Non-Operating Income | NA | 47.17 | 41.36 | 79.60 | 45.08 |
Interest Expense | NA | 24.83 | 91.43 | 162.47 | 69.77 |
Pretax Income | NA | 689.80 | 1,019.83 | 974.82 | 1,086.28 |
Income Taxes | NA | 55.45 | 214.41 | 205.00 | 228.63 |
Minority Interest | NA | 1.08 | 2.18 | 3.27 | 4.29 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 633.28 | 805.42 | 769.82 | 858.72 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 632.20 | 803.24 | 766.55 | 854.43 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 434.80 | 434.71 | 434.57 | 434.97 |
Diluted EPS Before Non-Recurring Items | NA | 1.99 | 1.85 | 2.40 | 1.96 |
Diluted Net EPS (GAAP) | NA | 1.44 | 1.85 | 1.77 | 1.96 |